Elevance Health (ELV) Earnings Put Its Fair Value Story To The Test
Elevance Health (ELV) heads into its third quarter 2026 earnings report on October 21, with market attention fixed on projected declines in profit, revenue, premiums, and membership in key insurance segments.
Recent trading has been resilient. Elevance Health’s share price return is up 14.78% over 90 days and 20.89% year to date, with the latest close at $428.26. The 1 year total shareholder return of 25.23% contrasts with a flat 3 year record and a modest 5 year gain of 6.32%.
Scan how Elevance Health compares with other insurers facing similar premium and earnings pressure by reviewing a curated set of 32 resilient stocks with low risk scores in the sector.
After a 1 year return of 25.23% and a long stretch of flatter results before that, Elevance Health now forces a harder question: Does the balance of risk and reward still lean toward new buyers at this price, or not?
Most Popular Narrative: 5.1% Undervalued
Against Elevance Health’s last close at $428.26, the most followed narrative points to a fair value of $451.38. This leaves a modest valuation gap that leans in favor of patient investors who care about earnings quality and cash generation.
The key requirement is that Elevance Health successfully manages Medicaid and Medicare Advantage margin targets while scaling Carelon’s complex and behavioral care programs and ACA bronze-plan strategy, without eroding earnings quality.
The view that Elevance Health is fairly valued implies that the current share price already reflects guidance for at least US$27 in adjusted 2026 EPS, at least US$26 as a 2027 baseline, and the planned return to at least 12% adjusted EPS growth from that base.
See why 116 investors see Elevance Health as 5% undervalued.
Result: Fair Value of $451.38 (UNDERVALUED)
Still, the thesis around Elevance Health can unravel quickly if Medicaid margins remain stuck near trough levels or if medical membership keeps sliding and weakens premium and fee income.
Find out about the key risks to this Elevance Health narrative.
Next Steps
Sentiment in this Elevance Health story is mixed, so do not wait for consensus to form before you review the data and stress test the assumptions yourself. To weigh those positives directly against the risks, start with the 4 key rewards.
Hunting For More Ideas Beyond Elevance Health?
If Elevance Health has sharpened your focus on quality and risk, do not stop here. Use these targeted screens to pressure test and broaden your watchlist.
- Target stronger risk control by reviewing a curated set of 32 resilient stocks with low risk scores that aim to keep drawdowns in check when conditions turn rough.
- Pursue better value entry points by scanning the 33 high quality undervalued stocks that combine quality fundamentals with pricing that still looks reasonable.
- Build a cash flow focused watchlist by filtering for income ideas through the 8 dividend fortresses and see which payouts look built to last.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com